



December 20, 2016

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2006-006410-15/ Novartis Protocol ID CRSV604A2201

*A multi-center, randomized, double-blinded, placebo-controlled, multiple dose study to assess the efficacy of intravenously administered RSV604 in immunocompromised adults with evidence of RSV infection*

Trial CRSV604A2201 was cancelled with no patient enrollment and as such, no results will be reported.